GelTex Eyes Polyamines/Polymers Combination From SunPharm Acquisition
Executive Summary
GelTex, developer of polymer-based pharmaceuticals, will test for complementary effects of combining polyamines and polymers following its acquisition of Jacksonville, Fla.-based SunPharm.
You may also be interested in...
GelTex To Discuss Anti-Obesity Collaboration With Roche, CEO Says
GelTex could begin discussions with Roche on a development agreement to improve Roche's anti-obesity therapy Xenical (orlistat), GelTex CEO Mark Skaletsky told financial analysts at the Hambrecht & Quist Health Care Conference in San Francisco Jan. 12.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials